Spelling suggestions: "subject:"escriptors"" "subject:"escriptora""
1 |
CRIPTO1: expressão e possíveis ações sobre as células citotrofoblásticas extravilosas humanas. / CRIPTO 1: expression and possible actions on human extravillous cytotrophoblastic cells.Bandeira, Carla Letícia dos Santos 30 March 2015 (has links)
CRIPTO 1 (CR1) é membro da família de fatores de crescimento epidermal-CRIPTO-1/FRL-1/Cryptic com funções específicas na embriogênese e tumores. Este estudo verificou a presença de CR1 em placentas saudáveis e com distúrbios de invasividade. Nossos resultados mostraram a expressão de CR3 e CR1 em placentas de primeiro e terceiro trimestre de gestação, respectivamente. Placentas acretas e coriocarcinomas também foram imunorreativos para CR1, principalmente em células citotrofoblásticas invasivas e malignas, respectivamente. A expressão de CR1 em células citotrofoblásticas extravilosas de primeiro trimestre prevaleceu em células em diferenciação e em células invasivas, sugerindo sua participação nesses processos. CR1 recombinante aumentou significativamente a invasão e migração em células HTR8/SV-neo, o que foi abolido na presença de RNA de interferência. Esses achados corroboram a ação dessa proteína sobre as células trofoblásticas. / CRYPTO 1 (CR1) is member of the family of epidermal growth factor-CRYPTO-1 / FRL-1 / Cryptic with specific roles in embryogenesis and tumors. This study investigated the presence of CR1 in healthy placentas and in placentas with invasive disorders. Our results showed the expression of CR3 and CR1 in the first and third trimester placentas, respectively. Placental choriocarcinoma and accreta placentas were also immunoreactive for CR1, especially in malignant and invasive cytotrophoblast cells, respectively. CR1 expression in first trimester extravillous cytotrophoblast cells prevailed in differentiating and invasive cells, suggesting a role in these processes. Recombinant CR1 significantly increased invasion and migration HTR8 / SV-Neo cells, which was abolished in the presence of interference RNA. These findings corroborate the action of this protein on the trophoblast cells.
|
2 |
Expressão do fator cripto-1 na interface materno-placentária em camundongos / Expression of Cripto-1 at mice maternal-placental interface.Bandeira, Carla Letícia dos Santos 24 November 2009 (has links)
Este estudo analisou a expressão gênica e o conteúdo protéico do fator Cripto 1 (Cr1) na interface materno-placentária ao longo da gestação através de RT-PCR e Western blotting. Nossos resultados mostraram que a proteína Cr1 está presente ao longo do desenvolvimento placentário nos dois compartimentos da interface materno-placentária. Houve aumento progressivo da proteína no compartimento fetal e, na decídua um decréscimo após o dia 13,5 de gestação, mas ainda com valores mais altos do que os da porção fetal da placenta. As avaliações semi-quantitativas de Cr1 por PCR indicaram uma baixa expressão nas fases de pós-implantação e final da gestação nos dois compartimentos estudados, com um aumento significativo nos dias 10,5 e principalmente no dia 13,5 de gestação. A presença de Cr1 na interface materno-placentária indica um papel relevante para este fator, possivelmente no desenvolvimento placentário ou ainda nos muitos processos que se desenvolvem neste sítio e que são essenciais para sua manutenção e sucesso gestacional. / This study analyzed the gene expression and protein content of Cripto 1 (Cr1) at the maternal-placental interface during gestation, through RT-PCR and Western Blotting. Our results showed that the protein Cr1 is present during placental development in both compartments of the maternal-placental interface. The content gradually increased at the fetal compartment, decreased at the decidua after day 13.5 of gestation, but nevertheless, as high values in comparison with those at the fetal compartment. The semi-quantitative evaluations of Cr1 through PCR indicated low expression at the post-implantation and final gestational periods in both compartments, showing a significant increase on day 10.5 and mainly 13.5 of gestation (p<0,05). The presence of Cr1 at the maternal-placental interface indicates a relevant role played by this factor, possibly during placental development or, yet, in the processes developed in this particular site and that are essential for gestational maintenance and success.
|
3 |
Expressão do fator cripto-1 na interface materno-placentária em camundongos / Expression of Cripto-1 at mice maternal-placental interface.Carla Letícia dos Santos Bandeira 24 November 2009 (has links)
Este estudo analisou a expressão gênica e o conteúdo protéico do fator Cripto 1 (Cr1) na interface materno-placentária ao longo da gestação através de RT-PCR e Western blotting. Nossos resultados mostraram que a proteína Cr1 está presente ao longo do desenvolvimento placentário nos dois compartimentos da interface materno-placentária. Houve aumento progressivo da proteína no compartimento fetal e, na decídua um decréscimo após o dia 13,5 de gestação, mas ainda com valores mais altos do que os da porção fetal da placenta. As avaliações semi-quantitativas de Cr1 por PCR indicaram uma baixa expressão nas fases de pós-implantação e final da gestação nos dois compartimentos estudados, com um aumento significativo nos dias 10,5 e principalmente no dia 13,5 de gestação. A presença de Cr1 na interface materno-placentária indica um papel relevante para este fator, possivelmente no desenvolvimento placentário ou ainda nos muitos processos que se desenvolvem neste sítio e que são essenciais para sua manutenção e sucesso gestacional. / This study analyzed the gene expression and protein content of Cripto 1 (Cr1) at the maternal-placental interface during gestation, through RT-PCR and Western Blotting. Our results showed that the protein Cr1 is present during placental development in both compartments of the maternal-placental interface. The content gradually increased at the fetal compartment, decreased at the decidua after day 13.5 of gestation, but nevertheless, as high values in comparison with those at the fetal compartment. The semi-quantitative evaluations of Cr1 through PCR indicated low expression at the post-implantation and final gestational periods in both compartments, showing a significant increase on day 10.5 and mainly 13.5 of gestation (p<0,05). The presence of Cr1 at the maternal-placental interface indicates a relevant role played by this factor, possibly during placental development or, yet, in the processes developed in this particular site and that are essential for gestational maintenance and success.
|
4 |
Rôle de CRIPTO dans la transition épithéliale-mésenchymateuse du cancer de la prostate et son impact sur la modulation de la communication intercellulaire / Role of CRIPTO in epithelial-mesenchymal transition in prostate cancer and it impact on the modulation of the intercellular communicationEl Sayed Hussein Jomaa, Ihsan 25 November 2016 (has links)
Le cancer de la prostate (CaP) représente le premier cancer chez l'homme et la seconde cause de mortalité. Alors que la plupart des malades atteints de cancer de la prostate évoluent favorablement (forme indolente), une fraction non négligeable développera une maladie agressive avec l’apparition de métastases. La recherche des biomarqueurs tumoraux peut aider à différencier les CaP dits indolent et les CaP agressifs qui sont responsables du décès des patients. Ils permettront de mieux sélectionner des patients afin d’éviter le surtraitement. La protéine CRIPTO est le premier membre de la superfamille des protéines EGF-CFC. Ce facteur de croissance est largement impliqué dans le développement embryonnaire et s'exprime dans de nombreux types de cancers. Son rôle dans le CaP reste encore non élucidé. L’objectif de mon travail de thèse consiste à examiner le profil d'expression de CRIPTO et d'évaluer son impact potentiel sur l’agressivité du cancer de la prostate.Les résultats ont montré que CRIPTO est exprimé de manière significative dans 37,9% de CaP. Il est absent voire faiblement détecté dans les prostates hyperplasiques bénignes et dans les tissus sains. Nous avons montré ensuite que la surexpression de CRIPTO favorise une transition épithéliale-mésenchymateuse (TEM) associée à l’augmentation de la capacité de migration et de la survie des cellules tumorales. Les voies de signalisation régulées par CRIPTO impliquent l’activation des voies PI3K / AKT et FGFR1 / ERK.De manière très intéressante, les cellules tumorales mésenchymateuses surexprimant CRIPTO secrètent excessivement des vésicules. Nous avons tenté alors de découvrir le rôle de ces vésicules dans la progression du cancer de la prostate. Les vésicules extracellulaires (VEs) purifiés étaient capables de moduler la signalisation du récepteur des androgènes et d’activer la voie du TGFß. Les cellules tumorales prostatiques traitées par ces VEs deviennent plus agressive et acquierent des caractéristiques mésenchymateuses.En conclusion, nos résultats mettent en évidence une nouvelle fonction importante de CRIPTO dans le cancer de la prostate. Nous démontrons également que les cellules tumorales surexprimant ce facteur de croissance secrètent excessivement des vésicules qui participent activement dans la communication intercellulaire et promeuvent la progression du CaP. L’ensemble de nos travaux suggère que le ciblage thérapeutique de CRIPTO et le blocage de la sécrétion des VEs pourraient être des nouvelles approches thérapeutiques innovantes pour le traitement du cancer de la prostate. / Prostate cancer (PCa) remains at the top of the list of the most common malignant tumors and the dominant cause of mortality and morbidity in men worldwide. Detection of tumor biomarkers to aid differentiate indolent from severe PCa cases and well-choose patients at high risk for intensive treatment. The founding member of EGF-CFC protein superfamily, CRIPTO, is widely implicated in embryonic development and is found to be expressed in a wide spectrum of human tumors. As its role in PCa was still unclear, we aimed to investigate expression profile of CRIPTO in PCa and relate its potential impact on prostate malignancy.Prostatic tissues and cell lines, both normal and cancerous, were engaged in experimental studies and design was based on techniques used in biochemistry, cellular and molecular biology.CRIPTO showed to be upregulated in 37.9% of PCas, while being absent or marginally detected in benign conditions. Our results displayed that CRIPTO overexpression promoted epithelial-mesenchymal transition (EMT) associated with enhanced migration capacity and survival under stress conditions due to propensity to stimulate PI3K/AKT and FGFR1/ERK signaling pathways.More interestingly, tumor mesenchymal like cells overexpressing CRIPTO secreted vesicles excessively. Thus we attempted to uncover the role of these vesicles in the progression of PCa. Extracellular vesicles derived from these cells were highly capable to modulate androgen receptor signaling through TGF-ß pathway and rendering the recipient prostatic cells more aggressive by acquisition of mesenchymal features.Our results highlight a new substantial function of CRIPTO in PCa and put in evidence its importance as a new promising target for PCa treatment. Moreover, we emphasize on an original role of mesenchymal extracellular vesicles in the interclonal communication to carry and transfer tumorigenic contents and enhance progression of PCa. This opens new scopes towards better understanding of vesicles secreted by prostate cancer cells and their impact to better cure the disease.
|
Page generated in 0.7156 seconds